ENO4: A Potential Drug Target Or Biomarker for Diseases (G387712)

Target Name: ENO4

NCBI ID: G387712

ENO4

ENO4: A Potential Drug Target Or Biomarker for Diseases

ENO4 (ENOS) is a gene that has been identified as a potential drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. ENO4 is a shortened form of the Enoyl-CoA reductase gene, which is responsible for the production of essential fatty acids, such as omega-3 and omega-6 fatty acids, in the body.

ENO4 has been shown to play a crucial role in the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that ENO4 mutations are associated with an increased risk of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. Additionally, ENO4 has been shown to be involved in the development of certain autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

Despite the potential implications of ENO4 as a drug target or biomarker, more research is needed to fully understand its role in these diseases. ENO4 has also been shown to be involved in the production of certain fatty acids, which could make it a potential target for drugs that target fatty acid metabolism. Additionally, ENO4 has been shown to be involved in the production of certain compounds that have been associated with certain diseases, such as heart disease and diabetes.

Overall, ENO4 is a gene that has the potential to be a drug target or biomarker for several diseases. Further research is needed to fully understand its role in these diseases and to develop treatments that target ENO4.

Protein Name: Enolase 4

Functions: May be required for sperm motility and function

The "ENO4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ENO4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets